Huapont Life Sciences Co Ltd (002004) - Net Assets
Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) has net assets worth CN¥16.96 Billion CNY (≈ $2.48 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥29.25 Billion ≈ $4.28 Billion USD) and total liabilities (CN¥12.29 Billion ≈ $1.80 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002004 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥16.96 Billion |
| % of Total Assets | 57.99% |
| Annual Growth Rate | 24.55% |
| 5-Year Change | 7.3% |
| 10-Year Change | 58.62% |
| Growth Volatility | 44.4 |
Huapont Life Sciences Co Ltd - Net Assets Trend (2001–2025)
This chart illustrates how Huapont Life Sciences Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Huapont Life Sciences Co Ltd (002004) total market value.
Annual Net Assets for Huapont Life Sciences Co Ltd (2001–2025)
The table below shows the annual net assets of Huapont Life Sciences Co Ltd from 2001 to 2025. Also explore Huapont Life Sciences Co Ltd (002004) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥16.98 Billion ≈ $2.48 Billion |
+9.73% |
| 2024-12-31 | CN¥15.47 Billion ≈ $2.26 Billion |
-6.70% |
| 2023-12-31 | CN¥16.58 Billion ≈ $2.43 Billion |
+0.21% |
| 2022-12-31 | CN¥16.55 Billion ≈ $2.42 Billion |
+4.59% |
| 2021-12-31 | CN¥15.82 Billion ≈ $2.32 Billion |
+11.93% |
| 2020-12-31 | CN¥14.14 Billion ≈ $2.07 Billion |
+6.74% |
| 2019-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
+3.88% |
| 2018-12-31 | CN¥12.75 Billion ≈ $1.87 Billion |
-4.12% |
| 2017-12-31 | CN¥13.30 Billion ≈ $1.95 Billion |
+24.22% |
| 2016-12-31 | CN¥10.70 Billion ≈ $1.57 Billion |
+2.82% |
| 2015-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+81.62% |
| 2014-12-31 | CN¥5.73 Billion ≈ $838.76 Million |
+42.86% |
| 2013-12-31 | CN¥4.01 Billion ≈ $587.13 Million |
+35.69% |
| 2012-12-31 | CN¥2.96 Billion ≈ $432.69 Million |
+14.35% |
| 2011-12-31 | CN¥2.59 Billion ≈ $378.40 Million |
+149.66% |
| 2010-12-31 | CN¥1.04 Billion ≈ $151.57 Million |
+15.43% |
| 2009-12-31 | CN¥897.32 Million ≈ $131.31 Million |
+10.23% |
| 2008-12-31 | CN¥814.07 Million ≈ $119.12 Million |
+11.38% |
| 2007-12-31 | CN¥730.86 Million ≈ $106.95 Million |
+39.77% |
| 2006-12-31 | CN¥522.90 Million ≈ $76.52 Million |
+18.66% |
| 2005-12-31 | CN¥440.68 Million ≈ $64.49 Million |
+9.72% |
| 2004-12-31 | CN¥401.64 Million ≈ $58.77 Million |
+175.58% |
| 2003-12-31 | CN¥145.74 Million ≈ $21.33 Million |
+42.64% |
| 2002-12-31 | CN¥102.18 Million ≈ $14.95 Million |
+16.80% |
| 2001-12-31 | CN¥87.48 Million ≈ $12.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Huapont Life Sciences Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9847.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.82 Billion | 17.77% |
| Other Components | CN¥8.40 Billion | 82.23% |
| Total Equity | CN¥10.22 Billion | 100.00% |
Huapont Life Sciences Co Ltd Competitors by Market Cap
The table below lists competitors of Huapont Life Sciences Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sichuan Chengfei Integration Technology Corp Ltd
SHE:002190
|
$1.27 Billion |
|
Bitfarms Ltd.
NASDAQ:KEEL
|
$1.27 Billion |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
$1.27 Billion |
|
Rami Levi
TA:RMLI
|
$1.27 Billion |
|
Trident Limited
NSE:TRIDENT
|
$1.27 Billion |
|
China Security & Fire Co Ltd Class A
SHG:600654
|
$1.27 Billion |
|
Kidswant Children Products Co.Ltd.
SHE:301078
|
$1.27 Billion |
|
COSMO Pharmaceuticals SA
SW:COPN
|
$1.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Huapont Life Sciences Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,337,058,000 to 10,219,770,870, a change of 882,712,870 (9.5%).
- Net income of 713,188,344 contributed positively to equity growth.
- Dividend payments of 668,497,085 reduced retained earnings.
- Other comprehensive income decreased equity by 1,009,823,000.
- Other factors increased equity by 1,847,844,610.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥713.19 Million | +6.98% |
| Dividends Paid | CN¥668.50 Million | -6.54% |
| Other Comprehensive Income | CN¥-1.01 Billion | -9.88% |
| Other Changes | CN¥1.85 Billion | +18.08% |
| Total Change | CN¥- | 9.45% |
Book Value vs Market Value Analysis
This analysis compares Huapont Life Sciences Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 49.81x to 0.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.09 | CN¥4.39 | x |
| 2002-12-31 | CN¥0.10 | CN¥4.39 | x |
| 2003-12-31 | CN¥0.15 | CN¥4.39 | x |
| 2004-12-31 | CN¥0.38 | CN¥4.39 | x |
| 2005-12-31 | CN¥0.43 | CN¥4.39 | x |
| 2006-12-31 | CN¥0.46 | CN¥4.39 | x |
| 2007-12-31 | CN¥0.67 | CN¥4.39 | x |
| 2008-12-31 | CN¥0.76 | CN¥4.39 | x |
| 2009-12-31 | CN¥0.85 | CN¥4.39 | x |
| 2010-12-31 | CN¥0.99 | CN¥4.39 | x |
| 2011-12-31 | CN¥2.41 | CN¥4.39 | x |
| 2012-12-31 | CN¥2.14 | CN¥4.39 | x |
| 2013-12-31 | CN¥2.66 | CN¥4.39 | x |
| 2014-12-31 | CN¥3.51 | CN¥4.39 | x |
| 2015-12-31 | CN¥5.09 | CN¥4.39 | x |
| 2016-12-31 | CN¥4.76 | CN¥4.39 | x |
| 2017-12-31 | CN¥4.69 | CN¥4.39 | x |
| 2018-12-31 | CN¥4.47 | CN¥4.39 | x |
| 2019-12-31 | CN¥4.67 | CN¥4.39 | x |
| 2020-12-31 | CN¥4.88 | CN¥4.39 | x |
| 2021-12-31 | CN¥5.11 | CN¥4.39 | x |
| 2022-12-31 | CN¥5.15 | CN¥4.39 | x |
| 2023-12-31 | CN¥5.10 | CN¥4.39 | x |
| 2024-12-31 | CN¥4.73 | CN¥4.39 | x |
| 2025-12-31 | CN¥5.16 | CN¥4.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Huapont Life Sciences Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.98%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.19%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.84x
- Recent ROE (6.98%) is below the historical average (12.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 35.56% | 17.87% | 1.30x | 1.52x | CN¥22.36 Million |
| 2002 | 37.05% | 18.63% | 0.97x | 2.06x | CN¥27.23 Million |
| 2003 | 27.61% | 16.60% | 1.07x | 1.56x | CN¥25.46 Million |
| 2004 | 12.59% | 17.48% | 0.57x | 1.27x | CN¥9.81 Million |
| 2005 | 12.18% | 19.20% | 0.57x | 1.11x | CN¥9.41 Million |
| 2006 | 14.23% | 22.28% | 0.38x | 1.70x | CN¥19.08 Million |
| 2007 | 30.83% | 41.93% | 0.45x | 1.63x | CN¥139.49 Million |
| 2008 | 11.79% | 15.70% | 0.50x | 1.51x | CN¥13.51 Million |
| 2009 | 15.24% | 23.45% | 0.48x | 1.36x | CN¥43.89 Million |
| 2010 | 13.54% | 24.40% | 0.40x | 1.39x | CN¥34.49 Million |
| 2011 | 12.76% | 48.54% | 0.15x | 1.75x | CN¥65.97 Million |
| 2012 | 12.39% | 8.57% | 0.65x | 2.21x | CN¥64.12 Million |
| 2013 | 7.97% | 6.78% | 0.58x | 2.01x | CN¥-77.04 Million |
| 2014 | 7.70% | 8.82% | 0.36x | 2.43x | CN¥-128.39 Million |
| 2015 | 6.69% | 10.31% | 0.31x | 2.07x | CN¥-315.69 Million |
| 2016 | 5.88% | 7.99% | 0.29x | 2.51x | CN¥-397.66 Million |
| 2017 | 5.33% | 5.51% | 0.32x | 3.06x | CN¥-443.51 Million |
| 2018 | 5.59% | 4.79% | 0.40x | 2.93x | CN¥-400.05 Million |
| 2019 | 6.64% | 6.15% | 0.38x | 2.85x | CN¥-313.87 Million |
| 2020 | 6.77% | 5.99% | 0.39x | 2.93x | CN¥-311.22 Million |
| 2021 | 6.61% | 5.37% | 0.41x | 2.97x | CN¥-343.13 Million |
| 2022 | 4.25% | 3.28% | 0.44x | 2.95x | CN¥-585.71 Million |
| 2023 | 2.99% | 2.61% | 0.38x | 3.04x | CN¥-708.40 Million |
| 2024 | -3.20% | -2.56% | 0.40x | 3.15x | CN¥-1.23 Billion |
| 2025 | 6.98% | 6.19% | 0.40x | 2.84x | CN¥-308.79 Million |
Industry Comparison
This section compares Huapont Life Sciences Co Ltd's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $1,949,079,902
- Average return on equity (ROE) among peers: -47.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Huapont Life Sciences Co Ltd (002004) | CN¥16.96 Billion | 35.56% | 0.72x | $1.27 Billion |
| Hubei Yihua Chemical Industry Co Ltd (000422) | $8.07 Billion | 0.44% | 3.96x | $1.87 Billion |
| Nanjing Red Sun Co Ltd (000525) | $725.57 Million | 4.67% | 1.78x | $864.24 Million |
| ADAMA Ltd (000553) | $310.27 Million | 16.23% | 1.37x | $1.78 Billion |
| Grand Industrial Holding Co Ltd (000626) | $1.45 Billion | 16.03% | 4.53x | $658.32 Million |
| Sichuan Meifeng Chemical Industry Co Ltd (000731) | $630.20 Million | 9.70% | 0.23x | $636.86 Million |
| Qinghai Salt Lake Industry Co.Ltd (000792) | $687.57 Million | 11.78% | 0.49x | $19.35 Billion |
| Asia Potash International Investment Guangzhou Co Ltd (000893) | $446.87 Million | 6.25% | 2.15x | $5.30 Billion |
| Hubei Xinyangfeng Fertilizer Co Ltd (000902) | $6.70 Billion | 9.72% | 0.45x | $2.54 Billion |
| Sichuan Lutianhua Co Ltd (000912) | $115.38 Million | -552.26% | 65.43x | $940.74 Million |
| Guangxi Hechi Chemical Co Ltd (000953) | $360.37 Million | 3.35% | 1.61x | $318.24 Million |
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. It is involved in the production and sale of pharmaceutical preparations and raw materials. The company also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more